Loureirin CCAS# 116384-24-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 116384-24-8 | SDF | Download SDF |
| PubChem ID | 14157896 | Appearance | Powder |
| Formula | C16H16O4 | M.Wt | 272.3 |
| Type of Compound | Chalcones | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)propan-1-one | ||
| SMILES | COC1=C(C=CC(=C1)O)CCC(=O)C2=CC=C(C=C2)O | ||
| Standard InChIKey | LCKRZXFBCWYAKU-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C16H16O4/c1-20-16-10-14(18)8-4-12(16)5-9-15(19)11-2-6-13(17)7-3-11/h2-4,6-8,10,17-18H,5,9H2,1H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Loureirin C can inhibit the activities of thrombin in vitro effectively. |
| In vitro | A Systematic Review of the Botanical, Phytochemical and Pharmacological Profile of Dracaena cochinchinensis, a Plant Source of the Ethnomedicine "Dragon's Blood".[Reference: WebLink]Molecules, 2014, 19(7):10650-10669.
Virtual screening and activities in vitro of active components from total phenols part of dragon's blood on promoting blood circulation[Reference: WebLink]Beijing Ligong Daxue Xuebao/Transaction of Beijing Institute of Technology, 2015, 35(2):218-220.
|
Loureirin C Dilution Calculator
Loureirin C Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.6724 mL | 18.3621 mL | 36.7242 mL | 73.4484 mL | 91.8105 mL |
| 5 mM | 0.7345 mL | 3.6724 mL | 7.3448 mL | 14.6897 mL | 18.3621 mL |
| 10 mM | 0.3672 mL | 1.8362 mL | 3.6724 mL | 7.3448 mL | 9.1811 mL |
| 50 mM | 0.0734 mL | 0.3672 mL | 0.7345 mL | 1.469 mL | 1.8362 mL |
| 100 mM | 0.0367 mL | 0.1836 mL | 0.3672 mL | 0.7345 mL | 0.9181 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2alpha-hydroxy-3beta-acetyloxy-betulic acid
Catalog No.:BCN3072
CAS No.:1163728-89-9
- Acetylexidonin
Catalog No.:BCN3279
CAS No.:116368-90-2
- Fumonisin B1
Catalog No.:BCC2461
CAS No.:116355-83-0
- SKF 86002 dihydrochloride
Catalog No.:BCC7236
CAS No.:116339-68-5
- Sarafotoxin S6b
Catalog No.:BCC5720
CAS No.:116303-65-2
- Clemizole hydrochloride
Catalog No.:BCC1486
CAS No.:1163-36-6
- 6-Aldehydoisoophiopogonanone A
Catalog No.:BCN2860
CAS No.:116291-82-8
- Pyrroside B
Catalog No.:BCN4042
CAS No.:116271-35-3
- MCB-613
Catalog No.:BCC3982
CAS No.:1162656-22-5
- Levobetaxolol HCl
Catalog No.:BCC4671
CAS No.:116209-55-3
- Aflatoxin B1
Catalog No.:BCC9212
CAS No.:1162-65-8
- Complanatoside
Catalog No.:BCN8213
CAS No.:116183-66-5
- 3',4',7-Trimethoxyflavan
Catalog No.:BCN6042
CAS No.:116384-26-0
- Z-Tyr-OH
Catalog No.:BCC2747
CAS No.:1164-16-5
- Androstanolone acetate
Catalog No.:BCC8826
CAS No.:1164-91-6
- SR 3576
Catalog No.:BCC7999
CAS No.:1164153-22-3
- 9S-10alpha-Hydroxyepigambogic acid
Catalog No.:BCN3080
CAS No.:1164201-85-7
- Fargesone A
Catalog No.:BCN6417
CAS No.:116424-69-2
- Fargesone B
Catalog No.:BCN6415
CAS No.:116424-70-5
- Aerugidiol
Catalog No.:BCN3529
CAS No.:116425-35-5
- Curcumadione
Catalog No.:BCN3525
CAS No.:116425-36-6
- Sal 003
Catalog No.:BCC2465
CAS No.:1164470-53-4
- ML 145
Catalog No.:BCC7876
CAS No.:1164500-72-4
- 5,5'-Dimethoxylariciresinol
Catalog No.:BCN6043
CAS No.:116498-58-9
[Identification of active components in Longxue Tongluo Capsules against ischemic brain injury based on component-activity relationship].[Pubmed:30868826]
Zhongguo Zhong Yao Za Zhi. 2019 Jan;44(1):150-157.
Ten fractions(A-J) were prepared by separation of Longxue Tongluo Capsules(LTC) by using silica gel column chromatography and orthogonal experimental design,showing similar chemical profiles with different abundances of peaks.These ten samples were assessed with UHPLC-QE OrbitrapHRMS for 97 common peaks.For the pharmacological activity experiment,three kinds of in vitro cell models including lipopolysaccharide(LPS)-induced BV-2 microglial cells NO release model,oxygen-glucose deprivation/reoxygenation(OGD/R)-treated HUVEC vascular endothelial cells injury model,and OGD/R-treated PC-12 nerve cells injury model were employed to evaluated the bioactivity of each fraction.Based on the contribution of each identified component,grey relation analysis and partial least squares(PLS) analysis were performed to establish component-activity relationship of LTC,identify the potential active components.After that,validation of the potential active components in LTC was carried out by using the same models.The results indicated that 4 phenolic compounds including 7,4'-dihydroxyhomoisoflavanone,Loureirin C,4,4'-dihydroxy-2,6-dimethoxydihydrochalcone,and homoisosocotrin-4'-ol,might be the active components for anti-neuroinflammation effect;five phenolic compounds such as 3,5,7,4'-tetrahydroxyhomoisoflavanone,loureirin D,7,4'-dihydroxyhomoisoflavane,and 5,7-dihydroxy-4'-methoxy-8-methyflavane,might have positive effects on the vascular endothelial injury;three phenolic compounds including 5,7,4'-trihydroxyflavanone,7,4'-dihydroxy-5-methoxyhomoisoflavane,and loureirin D,might be the active components in LTC against neuronal injury.
Metabolic profiling of five flavonoids from Dragon's Blood in human liver microsomes using high-performance liquid chromatography coupled with high resolution mass spectrometry.[Pubmed:28376352]
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 1;1052:91-102.
Although much is known about the pharmacological activities of Dragon's Blood (DB, a traditional Chinese herb), its metabolism in human liver microsomes (HLMs) and the cytochrome P450 (CYP) enzymes has not been studied. This study aims to identify the metabolic profile of five flavonoids (loureirin A, loureirin B, Loureirin C, 7,4'-dihydroxyflavone and 5,7,4'-trihydroxyflavanone) from DB in HLMs as well as the CYP enzymes that are involved in the metabolism of them. High-resolution mass spectrometry was used to characterize the structures of their metabolites and 10 cDNA-expressed CYP enzymes (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5) were used to verify which isozymes mediate in the metabolism of the metabolites. Totally, 29 metabolites including 10 metabolites of loureirin A, 10 metabolites of loureirin B, 4 metabolites of Loureirin C, 2 metabolites of 7,4'-dihydroxyflavone and 3 metabolites of 5,7,4'-trihydroxyflavanone were elucidated and identified on the basis of the high-resolution MS(n) data. The metabolic profile of the five flavonoids in HLMs involved hydroxylation, oxidation and demethylation. Among them, hydroxylation was the predominant biotransformation of the five flavonoids in HLMs, occurring in combination with other metabolic reactions. Assay with recombinant P450s revealed that CYP2C9 and CYP2C19 played an important role in the hydroxylation of flavonoids in HLMs. To the best of our knowledge, this is the first in vitro evaluation of the metabolic profile of loureirin A, loureirin B, Loureirin C, 7,4'-dihydroxyflavone and 5,7,4'-trihydroxyflavanone in HLMs.
Development and application of an UHPLC-MS method for comparative pharmacokinetic study of phenolic components from dragon's blood in rats under simulated microgravity environment.[Pubmed:26799977]
J Pharm Biomed Anal. 2016 Mar 20;121:91-98.
Dragon's blood is a commonly used Chinese herbal medicine shown to have protective effects in simulated microgravity in rats and mice. The current study aimed to develop an ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS) method for simultaneous determination of four phenolic components from the herb: loureirin A, Loureirin C, 7,4'-dihydroxyflavone and pterostilbene in rats, and use the method for comparative study on the pharmacokinetics (PK) and excretion of these components in rats after oral dosage of dragon's blood under simulated microgravity environments. The results showed the developed UHPLC-MS method was sensitive and rapid. The comparative pharmacokinetic study in rats showed loureirin A, Loureirin C and 7,4-dihydroxyflavone had decreased Cmax and AUC and increased Vd and CL in simulated microgravity environment; but pterostilbene had the opposite changes. The four phenolic components also showed increased or decreased excretions in simulated microgravity rats. These results indicate the chemical structure and physicochemical property, as well as physiological conditions may have an impact on the absorption and excretion of phenolic components in simulated microgravity environment. It also implies that different drug may behave differently in the same spaceflight condition leading to an increase or a reduction in pharmacodynamic outcomes.
A systematic review of the botanical, phytochemical and pharmacological profile of Dracaena cochinchinensis, a plant source of the ethnomedicine "dragon's blood".[Pubmed:25054444]
Molecules. 2014 Jul 22;19(7):10650-69.
"Dragon's blood" is the name given to a deep red resin obtained from a variety of plant sources. The resin extracted from stems of Dracaena cochinchinensis is one such source of "dragon's blood". It has a reputation for facilitating blood circulation and dispersing blood stasis. In traditional Chinese medicine, this resinous medicine is commonly prescribed to invigorate blood circulation for the treatment of traumatic injuries, blood stasis and pain. Modern pharmacological studies have found that this resinous medicine has anti-bacterial, anti-spasmodic, anti-inflammatory, analgesic, anti-diabetic, and anti-tumor activities, while it is also known to enhance immune function, promote skin repair, stop bleeding and enhance blood circulation. Various compounds have been isolated from the plant, including loureirin A, loureirin B, Loureirin C, cochinchinenin, socotrin-4'-ol, 4',7-dihydroxyflavan, 4-methylcholest-7-ene-3-ol, ethylparaben, resveratrol, and hydroxyphenol. The present review summarizes current knowledge concerning the botany, phytochemistry, pharmacological effects, toxicology studies and clinical applications of this resinous medicine as derived from D. cochinchinenesis.
